BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23190608)

  • 21. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
    Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
    Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.
    Hao M; Zhang L; An G; Meng H; Han Y; Xie Z; Xu Y; Li C; Yu Z; Chang H; Qiu L
    Leuk Lymphoma; 2011 Sep; 52(9):1787-94. PubMed ID: 21534877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-29b Downregulation by p53/Sp1 Complex Plays a Critical Role in Bleb Scar Formation After Glaucoma Filtration Surgery.
    Li N; Wang Z; Yang F; Hu W; Zha X; Duan X
    Transl Vis Sci Technol; 2023 Dec; 12(12):5. PubMed ID: 38051266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IFN-γ-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1.
    Yuan L; Zhou C; Lu Y; Hong M; Zhang Z; Zhang Z; Chang Y; Zhang C; Li X
    Cancer Lett; 2015 Apr; 359(1):136-47. PubMed ID: 25592039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
    Zou P; Kawada J; Pesnicak L; Cohen JI
    J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.
    Botta C; Cucè M; Pitari MR; Caracciolo D; Gullà A; Morelli E; Riillo C; Biamonte L; Gallo Cantafio ME; Prabhala R; Mignogna C; Di Vito A; Altomare E; Amodio N; Di Martino MT; Correale P; Rossi M; Giordano A; Munshi NC; Tagliaferri P; Tassone P
    Leukemia; 2018 Apr; 32(4):1003-1015. PubMed ID: 29158557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The micros in harmony: microRNA and microenvironment.
    Balakrishnan K; Gandhi V
    Leuk Lymphoma; 2011 Sep; 52(9):1626-9. PubMed ID: 21740342
    [No Abstract]   [Full Text] [Related]  

  • 30. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-29b regulates ethanol-induced neuronal apoptosis in the developing cerebellum through SP1/RAX/PKR cascade.
    Qi Y; Zhang M; Li H; Frank JA; Dai L; Liu H; Chen G
    J Biol Chem; 2014 Apr; 289(14):10201-10. PubMed ID: 24554719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
    de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
    PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long noncoding RNA TUG1 promotes proliferation and inhibits apoptosis in multiple myeloma by inhibiting miR-29b-3p.
    Liu D; Wang J; Liu M
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30842339
    [No Abstract]   [Full Text] [Related]  

  • 35. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
    Chen L; Wang S; Zhou Y; Wu X; Entin I; Epstein J; Yaccoby S; Xiong W; Barlogie B; Shaughnessy JD; Zhan F
    Blood; 2010 Jan; 115(1):61-70. PubMed ID: 19837979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
    Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
    Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.